Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of rF1V Plague Vaccine in Healthy Adults
NCT01122784Phase 2Completed
- Sponsor
- DynPort Vaccine Company
- Start
- Jul 2010
- Primary completion
- May 2012
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of rF1V vaccine in plague (4 arms), sponsored by DynPort Vaccine Company. Primary endpoint: Frequency and severity of local and systemic adverse events at Day 210. Started Jul 2010; status: completed.
02
Drugs
rF1V vaccine
03
Conditions
plague
Beyond the preview
Go deeper on NCT01122784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01122784.